Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Short term Debt (2016 - 2025)

Gsk has reported Short term Debt over the past 10 years, most recently at $4.0 billion for Q4 2025.

  • Quarterly results put Short term Debt at $4.0 billion for Q4 2025, up 32.89% from a year ago — trailing twelve months through Dec 2025 was $4.0 billion (up 32.89% YoY), and the annual figure for FY2025 was $4.0 billion, up 32.89%.
  • Short term Debt for Q4 2025 was $4.0 billion at Gsk, up from $3.0 billion in the prior quarter.
  • Over the last five years, Short term Debt for GLAXF hit a ceiling of $4.0 billion in Q4 2025 and a floor of $1.3 billion in Q4 2021.
  • Median Short term Debt over the past 5 years was $3.0 billion (2024), compared with a mean of $2.7 billion.
  • Biggest five-year swings in Short term Debt: skyrocketed 129.86% in 2023 and later decreased 13.24% in 2024.
  • Gsk's Short term Debt stood at $1.3 billion in 2021, then increased by 17.08% to $1.5 billion in 2022, then skyrocketed by 129.86% to $3.5 billion in 2023, then fell by 13.24% to $3.0 billion in 2024, then soared by 32.89% to $4.0 billion in 2025.
  • The last three reported values for Short term Debt were $4.0 billion (Q4 2025), $3.0 billion (Q4 2024), and $3.5 billion (Q4 2023) per Business Quant data.